Bellevue Group Ag Uni Qure N.V. Transaction History

Bellevue Group Ag

$4.67 Billion
Q3 2025

A detailed history of Bellevue Group Ag transactions in Uni Qure N.V. stock. As of the latest transaction made, Bellevue Group Ag holds 4,763 shares of QURE stock, worth $142,318. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,763

Previous 19,610 75.71%

Holding current value

$142,318

Previous $273,000 1.83%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$13.28 - $59.4 $197,168 - $881,911	-14,847 Reduced 75.71%	4,763 $278,000
Q2 2025 Aug 14, 2025	SELL	$8.34 - $17.27 $24,102 - $49,910	-2,890 Reduced 12.84%	19,610 $273,000
Q4 2024 Feb 14, 2025	BUY	$4.54 - $17.73 $102,150 - $398,925	22,500 New	22,500 $397,000
Q2 2021 Aug 12, 2021	SELL	$29.97 - $37.17 $1.03 Million - $1.28 Million	-34,500 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$45.06 - $67.74 $135,180 - $203,219	3,000 Added 9.52%	34,500 $1.56 Million

Q1 2020 May 14, 2020	BUY	$40.01 - $73.97 $104,026 - $192,322	2,600 Added 9.0%	31,500 $1.5 Million
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $74,260 - $149,240	-2,000 Reduced 6.47%	28,900 $2.07 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $129,888 - $253,440	3,300 Added 11.96%	30,900 $1.22 Million
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $564,532 - $879,433	-10,700 Reduced 27.94%	27,600 $2.16 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $775,137 - $1.94 Million	28,300 Added 283.0%	38,300 $2.29 Million
Q4 2018 Feb 12, 2019	SELL	$22.8 - $33.93 $225,720 - $335,907	-9,900 Reduced 49.75%	10,000 $288,000
Q3 2018 Nov 13, 2018	SELL	$29.75 - $43.08 $8,925 - $12,924	-300 Reduced 1.49%	19,900 $724,000
Q2 2018 Aug 07, 2018	BUY	$21.96 - $39.94 $443,592 - $806,788	20,200 New	20,200 $764,000

Others Institutions Holding QURE

# of Institutions

267

Shares Held

51.1M

Call Options Held

3.92M

Put Options Held

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $1.4B
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Uni Qure N.V. Transaction History